Unilife Corporation Announces Financial Results For Fiscal Year 2013 Third Quarter

Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended March 31, 2013, (the third quarter of Fiscal Year 2013).

Recent Highlights

• In April, Unilife signed a 15-year customization and commercial supply contract with a U.S. pharmaceutical company for the EZMix^™ dual-chamber syringe. This contract is expected to generate up to $110 million in cumulative revenue from customization programs, production scale-up, device sales and a royalty from net drug sales.
  Tags: Healthcare NASDAQ Financial Results Up on News Interesting News
  
  

  Tweet
  Read more

  Add comment (0)

CardioComm Solutions Files New Patents for Automated Enabling of Over-The-Counter, Consumer, Bio-Monitoring Devices for Home Monitoring and Remote Diagnostic Interpretation

The HeartCheck PEN ECG device is the first to utilize the patent pending SMART Monitoring technologies to enable/unlock a consumer medical devices to record, display, transmit and receive bio-signals and images.

CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today confirmed it has filed for U.S. and Canadian patents for use of their proprietary technologies in the automated, software enabled and server based unlocking of over-the-counter ("OTC"), consumer based, bio-monitoring devices. Under the U.S and Canadian patents, filed on May 6, 2013 and May 8, 2013 respectively, the Company will be permitted to apply the statement "Patent Pending SMART Monitoring Technologies" in its corporate materials until the application process has been completed.

STAAR Surgical Reports Strong First Quarter 2013 Financial Results

~Total Sales of $18 Million Increased 16% from Q1 2012 / 21% Increase on Constant Currency Basis
~~Visian® ICL™ Sales Grew 24% to Record $10.6 Million
~~nanoFLEX™ Toric IOL Launched for Europe
~~GAAP Net Income of $0.01 per share, Non GAAP Adjusted Net Income of $0.08 company Continues to Invest to Drive Top and Bottom Line Growth

STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported record revenue for the first quarter ended March 29, 2013 of $18.0 million compared to $15.5 million reported for the first quarter of 2012. 

Bayer HealthCare to Acquire Conceptus(R)